Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus
| Autor: | Malhar Agarwal, Naji Maaliki, Fabiana Rollini, Theodore A. Bass, Jose Rivas Rios, Siva Suryadevara, Gabriel Silva, Andres M. Pineda, Daniel Soffer, Lisa K. Jennings, Maryuri Briceno, Victor Kairouz, Andrea Rivas, Mustafa Wali, Francesco Franchi, Ahmed Nawaz, Dominick J. Angiolillo, Jason A. Piraino, Zubair Shaikh, Latonya Been, Martin M. Zenni |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
lcsh:Diseases of the circulatory (Cardiovascular) system medicine.medical_specialty Aspirin business.industry Thrombogenicity 030204 cardiovascular system & hematology medicine.disease Clopidogrel Blockade 03 medical and health sciences 030104 developmental biology 0302 clinical medicine lcsh:RC666-701 Pharmacodynamics Diabetes mellitus Internal medicine medicine Cardiology Platelet Cardiology and Cardiovascular Medicine business Vorapaxar medicine.drug |
| Zdroj: | JACC: Basic to Translational Science, Vol 4, Iss 7, Pp 763-775 (2019) |
| ISSN: | 2452-302X |
| DOI: | 10.1016/j.jacbts.2019.07.011 |
| Popis: | Summary: Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown. Moreover, although withdrawal of aspirin has emerged as a bleeding reduction strategy, the PD effects of stopping aspirin in patients treated with vorapaxar also are unknown. In this prospective PD investigation, vorapaxar was associated with reduced platelet-mediated thrombogenicity without affecting clot kinetics irrespective of DM status. However, platelet-mediated thrombogenicity increased after aspirin withdrawal, particularly among patients with DM. (Optimizing anti-Platelet Therapy In diabetes MellitUS-5 Study [OPTIMUS-5]; NCT02548650) Key Words: dual antiplatelet therapy, pharmacodynamics, platelets, thrombin, vorapaxar |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|